Related Experiment Video
Updated: Mar 22, 2026

In Vivo Evaluation of the Mechanical and Viscoelastic Properties of the Rat Tongue
Published on: July 6, 2017
Pharyngeal collapsibility during sleep is elevated in insulin-resistant females with morbid obesity
Oscar L Llanos1, Panagis Galiatsatos2, Edmarie Guzmán-Vélez3
1Dept of Medicine, University of Arkansas, Little Rock, AR, USA.
Abstract:
Insulin resistance is associated with sleep apnoea, leading us to hypothesise that it is also associated with elevations in pharyngeal collapsibility, even in the absence of sleep apnoea.90 bariatric patients were characterised for sleep apnoea, pharyngeal collapsibility and insulin resistance. Patients with a respiratory disturbance index (RDI) >10 events·h(-1), diabetes mellitus, tonsillar hypertrophy and pulmonary disease were excluded. The remaining 14 females underwent collapsibility measurements (passive critical pressure, Pcritp ) during non-rapid eye movement sleep. The homeostasis model assessment (HOMA) index, a measure of insulin resistance, was derived from measurements of fasting glucose and insulin levels, and compared to Pcritp Groups with high Pcritp compared to low Pcritp did not differ in age, body mass index or RDI. HOMA and insulin were elevated in the high Pcritp group compared to the low Pcritp group (p<0.02). Pcritp correlated with HOMA (Spearman's ρ=0.565, 95% CI 0.104-0.862; p=0.035) and insulin (Spearman's ρ=0.609 95% CI 0.196-0.835; p=0.021).Obese insulin-resistant subjects without frank diabetes or sleep apnoea demonstrate preclinical elevations in pharyngeal collapsibility, which may increase their susceptibility to sleep apnoea. Our findings suggest that insulin resistance could play a significant role in sleep apnoea pathogenesis by generating requisite elevations in pharyngeal collapsibility.
Related Concept Videos
Sleep Apnea
The condition is more prevalent among...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Sleep-Wake Cycles
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
Obesity
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Hypoglycemia and Glucagon

